Polycythemia Vera: A Comprehensive Approach to Management
Review highlights current approaches to risk stratification, differential diagnosis, and the optimal use of current treatment options for polycythemia vera.
Myeloproliferative Neoplasms
Direct Oral Anticoagulants as Effective as Vitamin K Antagonists for Thromboembolic Events With Myeloproliferative Neoplasms
The efficacy and safety of direct oral anticoagulants and vitamin K antagonists in the treatment of ATEs/VTEs in patients with MPNs was compared.
Myeloproliferative Neoplasms: Driver Mutations Occur Decades Before Clinical Presentation
Detection of driver mutations acquired very early in life and life-long clonal expansion may predict clinical outcomes and interventions for patients with myeloproliferative neoplasms.
Mortality Rates, Diverse Causes of Death in Polycythemia Vera
Study results presented at the annual meeting of the American Society of Hematology suggest that the estimated 4-year mortality rate among patients with polycythemia vera is more than 10%, and that causes of death vary.
Personalized Diagnostic Model Differentiates Myelodysplastic Syndromes From Other Myeloid Malignancies
A geno-clinical model used mutational data and peripheral blood counts to accurately distinguish myelodysplastic syndromes from other myeloid malignancies.
Do Dietary Factors Influence Risk of Developing MPNs?
An analysis of data from the NIH-AARP Diet and Health Study evaluated the association between consumption of various foods and the development of MPN.
Integrative Medicine Therapies Effectively Increase Quality of Life for Patients With Myeloproliferative Neoplasms
An evaluation of more than 2 dozen types of integrative medicine therapies demonstrated that patients with MPNs who engaged in these activities had improved negative symptoms and quality of life.
Prevalence of Pulmonary Hypertension in Patients With Myeloproliferative Neoplasms
A new meta-analysis indicates that the true prevalence of pulmonary hypertension linked to myeloproliferative neoplasms is not well understood.
Promising Early Results for Ruxolitinib-Decitabine Combination in MPN in Accelerated and Blast Phases
A small, single-arm, phase 2 study results demonstrate efficacy and safety of this combination therapy in patients with MPN-AP or MPN-BP.
Polycythemia Vera and Essential Thrombocythemia: Diagnosis, Risk-Stratification, Management Updates
Investigators summarized current literature surrounding the diagnosis and risk-stratification of PV and ET, and reviewed available and upcoming therapies.
-
Loading...
-
Loading...
Next post in General Hematology
